Dr Mark Boyd

Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, vol. 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331

Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, vol. 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7

Boyd MA; Cooper DA, 2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, vol. 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4

Alvarez E; Belloso WH; Boyd MA; Inkaya AC; Hsieh E; Kambugu A; Kaminski G; Martinez E; Stellbrink HJ; Walmsley S, 2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, vol. 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269

Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, vol. 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS O', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0140623

Cummins NW; Neuhaus J; Chu H; Neaton J; Wyen C; Rockstroh JK; Skiest DJ; Boyd MA; Khoo S; Rotger M, 2015, 'Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis', EBioMedicine, vol. 2, pp. 706 - 712, http://dx.doi.org/10.1016/j.ebiom.2015.05.012

Boyd MA; Cooper DA, 2015, 'Novel antiretroviral agents and universal access to HIV care', The Lancet HIV, http://dx.doi.org/10.1016/S2352-3018(15)00244-1

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Boyd MA; Cooper DA, 2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, vol. 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8

Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, vol. 15, http://dx.doi.org/10.1186/s12879-015-1051-4

McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 131 - 139, http://dx.doi.org/10.3851/IMP2774

McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 255, http://dx.doi.org/10.3851/IMP2822

Boyd MA; Donovan B; Prestage G; Chen M; Petoumenos K; Gray R; Guy R; Rogers GB; Bourne C; Klausner JD, 2015, 'Is it time to rethink syphilis control?', Clinical Infectious Diseases, vol. 60, pp. 325 - 326, http://dx.doi.org/10.1093/cid/ciu813

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118228

Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, vol. 2, pp. 42 - 51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7

Han N; Wright ST; O'Connor CC; Hoy J; Ponnampalavanar S; Grotowski M; Zhao HX; Kamarulzaman A; Ellis D; Bloch M, 2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, vol. 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288

Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C, 2014, 'Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority', The Lancet, vol. 384, pp. 1942 - 1951, http://dx.doi.org/10.1016/S0140-6736(14)61170-3

Holt SG; Gracey DM; Levy MT; Mudge DW; Irish AB; Walker RG; Baer R; Sevastos J; Abbas R; Boyd MA, 2014, 'A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection', AIDS Research and Therapy, vol. 11, http://dx.doi.org/10.1186/1742-6405-11-35

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 161 - 168

Wright ST; Hoy J; Mulhall B; OʼConnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA, 2014, 'Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy', JAIDS Journal of Acquired Immune Deficiency Syndromes, vol. 66, pp. 55 - 64, http://dx.doi.org/10.1097/QAI.0000000000000125

Revell AD; Boyd MA; Wang D; Emery S; Gazzard B; Reiss P; van Sighem A; Montaner JS; Lane HC; Larder BA, 2014, 'A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy', HIV Medicine, vol. 15, pp. 442 - 448, http://dx.doi.org/10.1111/hiv.12156

Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0099530

Suzuki K; Hattori S; Marks K; Ahlenstiel C; Maeda Y; Ishida T; Millington M; Boyd M; Symonds G; Cooper DA, 2013, 'Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing', Molecular Therapy - Nucleic Acids, vol. 2, pp. e137, http://dx.doi.org/10.1038/mtna.2013.64

Martin A; Moore CL; Mallon PWG; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral t', PloS one, vol. 8

Achhra AC; Boyd MA, 2013, 'Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature', AIDS Research and Therapy, vol. 10, http://dx.doi.org/10.1186/1742-6405-10-33

Boyd M, 2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virologic', The Lancet, vol. 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2

Martin A; Moore C; Mallon PWG; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, vol. 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4

Boyd MA; Cooper DA, 2013, 'SPRING-2 the future of antiretroviral therapy', The Lancet Infectious Diseases, http://dx.doi.org/10.1016/S1473-3099(13)70194-4

Boyd MA; Donovan B, 2013, 'Antiretroviral therapy: Dolutegravir sets SAIL(ING)', The Lancet, vol. 382, pp. 664 - 666, http://dx.doi.org/10.1016/S0140-6736(13)61456-7

Wright ST; Petoumenos K; Boyd M; Carr A; Downing S; O'Connor CC; Grotowski M; Law MG, 2013, 'Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience', HIV Medicine, vol. 14, pp. 208 - 216, http://dx.doi.org/10.1111/j.1468-1293.2012.01053.x

Jansson J; Wilson DP; Carr A; Petoumenos K; Boyd MA, 2013, 'Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV', AIDS, vol. 27, pp. 1245 - 1251, http://dx.doi.org/10.1097/QAD.0b013e32835e163d

Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA, 2013, 'The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0054435

Wright S; Boyd MA; Yunihastuti E; Law M; Sirisanthana T; Hoy J; Pujari S; Lee MP; Petoumenos K, 2013, 'Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0064902

Byakwaga H; Petoumenos K; Ananworanich J; Zhang F; Boyd MA; Sirisanthana T; Li PCK; Lee C; Mean CV; Saphonn V, 2013, 'Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observationa', Journal of the International Association of Providers of AIDS Care, vol. 12, pp. 270 - 277, http://dx.doi.org/10.1177/1545109712469684

Jansson J; Wilson D; Carr A; Petoumenos K; Boyd M, 2012, 'Currently available medications may not be sufficient for lifelong treatment of HIV', JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 15, pp. 4 - 4, http://dx.doi.org/10.7448/IAS.15.6.18077

Boyd M, 2012, 'Dolutegravir-a promising antiretroviral in development', The Lancet Infectious Diseases, vol. 12, pp. 90 - 91, http://dx.doi.org/10.1016/S1473-3099(11)70291-2

Boyd M; Mohapi L, 2012, 'Stretching delivery of HIV health services', The Lancet, vol. 380, pp. 865 - 867, http://dx.doi.org/10.1016/S0140-6736(12)60952-0

Avihingsanon A; Van Der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K, 2012, 'Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study', AIDS Research and Human Retroviruses, vol. 28, pp. 1170 - 1176, http://dx.doi.org/10.1089/aid.2011.0247

McManus H; O'Connor CC; Boyd M; Broom J; Russell D; Watson K; Roth N; Read PJ; Petoumenos K; Law MG, 2012, 'Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0048839

Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Boyd MA; Cooper DA, 2012, 'Optimisation of HIV care and service delivery: Doing more with less', The Lancet, vol. 380, pp. 1860 - 1866, http://dx.doi.org/10.1016/S0140-6736(12)61154-4

Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; Allworth A; Anderson J; Baker D; Bloch M, 2012, 'Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0038377

Wilson DP; Grulich AE; Boyd M, 2011, 'Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men', Clinical Infectious Diseases, vol. 53, pp. 611 - 612, http://dx.doi.org/10.1093/cid/cir477

Revell AD; Wang D; Boyd MA; Emery S; Pozniak AL; De Wolf F; Harrigan R; Montaner JSG; Lane C; Larder BA, 2011, 'The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool', AIDS, vol. 25, pp. 1855 - 1863, http://dx.doi.org/10.1097/QAD.0b013e328349a9c2

Byakwaga H; Kelly M; Purcell DFJ; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 ⁺ T-cell response: A randomized controlle', Journal of Infectious Diseases, vol. 204, pp. 1532 - 1540, http://dx.doi.org/10.1093/infdis/jir559

Boyd MA; Nwizu CA, 2010, 'Operational research in HIV priority areas: the African way.', Lancet, vol. 376, pp. 4 - 6, http://dx.doi.org/10.1016/S0140-6736(10)60972-5

Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.', Pharmacoeconomics, vol. 28 Suppl 1, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000

Carey D; Amin J; Boyd M; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials', Journal of Antimicrobial Chemotherapy, vol. 65, pp. 1878 - 1888, http://dx.doi.org/10.1093/jac/dkq231

Boyd MA, 2010, 'Current and future management of treatment failure in low- and middle-income countries', Current Opinion in HIV and AIDS, vol. 5, pp. 83 - 89, http://dx.doi.org/10.1097/COH.0b013e328333b8c0

Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', PharmacoEconomics, vol. 28, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000

Zhou J; Li PCK; Kumarasamy N; Boyd M; Chen YMA; Sirisanthana T; Sungkanuparph S; Oka S; Tau G; Phanuphak P, 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, vol. 11, pp. 31 - 39, http://dx.doi.org/10.1111/j.1468-1293.2009.00738.x

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current Opinion in HIV and AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.0b013e328329fc8d

Boyd M; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', The Lancet, vol. 374, pp. 185 - 186, http://dx.doi.org/10.1016/S0140-6736(09)61313-1

Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4⁺ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, vol. 25, pp. 569 - 576, http://dx.doi.org/10.1089/aid.2008.0149

McIntyre GJ; Yu YH; Tran A; Jaramillo AB; Arndt AJ; Millington ML; Boyd MP; Elliott FA; Shen SW; Murray JM, 2009, 'Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success', Virology Journal, vol. 6, http://dx.doi.org/10.1186/1743-422X-6-184

Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, vol. 10, pp. 143 - 151, http://dx.doi.org/10.1111/j.1468-1293.2008.00663.x

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current opinion in HIV & AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.013e328329fc8d

Boyd M; Pett S, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', AUSTRALIAN PRESCRIBER, vol. 31, pp. 66 - 69, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000257656700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Boyd M; Byakwaga H, 2008, 'Considering the benefits of disease-specific interventions on overall public health', The Lancet Infectious Diseases, vol. 8, pp. 278, http://dx.doi.org/10.1016/S1473-3099(08)70080-X

Colebunders R; French M; Oelrichs R; Boyd M, 2008, 'Editorial introductions', Current Opinion in HIV and AIDS, vol. 3, http://dx.doi.org/10.1097/COH.0b013e32830890a4

Oelrichs R; Boyd M, 2008, 'Evidence and policy in the globalized response to AIDS', Current Opinion in HIV and AIDS, vol. 3, pp. 477 - 480, http://dx.doi.org/10.1097/COH.0b013e328303ba0b

Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A, 2008, 'A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)', Antiviral Therapy, vol. 13, pp. 449 - 453

Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A, 2007, 'A randomized study to evaluate injection site reactions (ISR) using three different mechanisms for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device', ANTIVIRAL THERAPY, vol. 12, pp. L57 - L57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249773400105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Boyd M, 2007, 'Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?', Expert Opinion on Pharmacotherapy, vol. 8, pp. 957 - 964, http://dx.doi.org/10.1517/14656566.8.7.957

Cooper D; Cahn P; Lewin S; Kaldor J; McClure C; Kort R; Boyd M, 2007, 'The Sydney Declaration: a call to scale up research', Lancet, vol. 370, pp. 7 - 8, http://dx.doi.org/10.1016/S0140-6736(07)61024-1

Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG, 2007, 'Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment', HIV Medicine, vol. 8, pp. 46 - 54, http://dx.doi.org/10.1111/j.1468-1293.2007.00427.x

Kerr SJ; Duncombe C; Avihingsanon A; Ananworanich J; Boyd M; Sopa B; Chuenyam T; Cooper DA; Lange JMA; Phanuphak P, 2007, 'Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens', Journal of the International Association of Physicians in AIDS Care, vol. 6, pp. 36 - 46, http://dx.doi.org/10.1177/1545109706295946

Boyd MA; Cooper DA, 2007, 'Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research', AIDS, vol. 21, http://dx.doi.org/10.1097/01.aids.0000279707.01557.b2

Autar RS; Boyd MA; Wit FWMN; Ruxrungtham K; Sankote J; Lange JMA; Cooper DA; Phanuphak P; Burger DM; Reiss P, 2007, 'Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen', Antiviral Therapy, vol. 12, pp. 1265 - 1271

Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EAM; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M, 2006, 'Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)', Antiviral Therapy, vol. 11, pp. 223 - 232

Boyd MA; Burger DM; Phanuphak P; Cooper DA, 2006, 'Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]', AIDS, vol. 20, pp. 1083 - 1085, http://dx.doi.org/10.1097/01.aids.0000222090.52035.b2

Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie PI; Uchaipichat V; Stek M; Lange JMA; Phanuphak P; Cooper DA; Udomuksorn W, 2006, 'Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir', Pharmacogenetics and Genomics, vol. 16, pp. 321 - 329, http://dx.doi.org/10.1097/01.fpc.0000197465.14340.d4

Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JMA; Phanuphak P; Cooper DA; Burger DM, 2006, 'The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity', Journal of Antimicrobial Chemotherapy, vol. 57, pp. 1161 - 1167, http://dx.doi.org/10.1093/jac/dkl112

Boyd MA; Carr A; Ruxrungtham K; Srasuebkul P; Bien D; Law M; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange JMA, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz', Journal of Infectious Diseases, vol. 194, pp. 642 - 650, http://dx.doi.org/10.1086/505709

Boyd MA; Dixit NM; Siangphoe U; Buss NE; Salgo MP; Lange JMA; Phanuphak P; Cooper DA; Perelson AS; Ruxrungtham K, 2006, 'Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012)', Journal of Infectious Diseases, vol. 194, pp. 1319 - 1322, http://dx.doi.org/10.1086/508291

Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J, 2005, 'Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients', Antiviral Therapy, vol. 10, pp. 301 - 307

Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JMA; Cooper DA; Phanuphak P, 2005, 'Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009', HIV Medicine, vol. 6, pp. 410 - 420, http://dx.doi.org/10.1111/j.1468-1293.2005.00327.x

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, vol. 7, pp. 552 - 564, http://dx.doi.org/10.1002/jgm.705

Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange PJ; Cooper PD; Phanuphak PP, 2004, 'Creation of a drug fund for post-clinical trial access to antiretrovirals', Lancet, vol. 364, pp. 101 - 102, http://dx.doi.org/10.1016/S0140-6736(04)16596-3

Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JMA; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, vol. 18, pp. 1169 - 1177, http://dx.doi.org/10.1097/00002030-200405210-00010

Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH, 2004, 'Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients', Journal of Clinical Pharmacology, vol. 44, pp. 793 - 802, http://dx.doi.org/10.1177/0091270004266489

Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J, 2003, 'Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients', Journal of Antimicrobial Chemotherapy, vol. 51, pp. 1231 - 1238, http://dx.doi.org/10.1093/jac/dkg198

Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; Van Heeswijk RPG; Lange JMA; Cooper DA; Phanuphak P; Burger DM, 2003, 'Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects', Journal of Acquired Immune Deficiency Syndromes, vol. 34, pp. 134 - 139, http://dx.doi.org/10.1097/00126334-200310010-00003

Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JMA; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, vol. 17, pp. 2191 - 2199, http://dx.doi.org/10.1097/00002030-200310170-00007

Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH, 2003, 'Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide', Journal of Clinical Pharmacology, vol. 43, pp. 1382 - 1391, http://dx.doi.org/10.1177/0091270003259220